TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04651959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVICOD 200 MG Film Tablet
Description: AVICOD is containing 200 mg favipiravir manufactured by Pharma Plant,Turkey.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVICOD 200 MG Film Tablet
Description: AVICOD is containing 200 mg favipiravir manufactured by Pharma Plant,Turkey.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVIGAN 200 MG Film Tablets
Description: AVIGAN is containing 200 mg favipiravir manufactured by Toyama, Japan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVIGAN 200 MG Film Tablets
Description: AVIGAN is containing 200 mg favipiravir manufactured by Toyama, Japan
Study: NCT00948805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH agonist
Description: 3,6mg of goserelin acetate, 250mg of hCG, FSH variable dose according to the number of days required for appropriate ovarian stimulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: 250mg of hCG, Zoladex, FSH variable dose according to the number of days required for appropriate ovarian stimulation
Study: NCT01895894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil 20\~30mg/kg/day PO until nephrotic syndrome relapse (max. 1 year)
Study: NCT03944122

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: therapeutical ultrasound were applied to the patients

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: therapeutical ultrasound were applied to the patients

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: therapeutical ultrasound were applied to the patients
Study: NCT02565381

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal nicotine patch
Description: * ≥10 cigarettes per day: nicotine 21mg/24hr patch daily x 6 weeks, then nicotine 14mg/24hr patch daily x 2 weeks~* \<10 cigarettes per day: nicotine 14mg/24hr patch daily x 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch
Description: * ≥10 cigarettes per day: nicotine 21mg/24hr patch daily x 6 weeks, then nicotine 14mg/24hr patch daily x 2 weeks~* \<10 cigarettes per day: nicotine 14mg/24hr patch daily x 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch
Description: * ≥10 cigarettes per day: nicotine 21mg/24hr patch daily x 6 weeks, then nicotine 14mg/24hr patch daily x 2 weeks~* \<10 cigarettes per day: nicotine 14mg/24hr patch daily x 8 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-person smoking cessation counseling
Description: - One-on-one 15-minute counseling sessions once per week for 8 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-person smoking cessation counseling
Description: - One-on-one 15-minute counseling sessions once per week for 8 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-person smoking cessation counseling
Description: - One-on-one 15-minute counseling sessions once per week for 8 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingent financial rewards for smoking abstinence
Description: - Escalating-value financial rewards for smoking abstinence, verified by exhaled carbon monoxide \<8ppm

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messages to support smoking abstinence
Description: - 1-5 text messages per day starting up to 2 weeks before the quit date and continuing until 6 weeks after the quit date, delivered by SmokefreeTXT
Study: NCT01696435

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3
Description: Vitamin D3 (cholecalciferol), 2000 IU per day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3
Description: Vitamin D3 (cholecalciferol), 2000 IU per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omega-3 fatty acids (fish oil)
Description: Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omega-3 fatty acids (fish oil)
Description: Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil placebo
Description: Fish oil placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil placebo
Description: Fish oil placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D placebo
Description: Vitamin D placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D placebo
Description: Vitamin D placebo
Study: NCT03748940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3074828
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3074828
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900021
Description: Administered SC
Study: NCT01462903

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tumor infiltrating lymphocytes, IL-2
Description: Biological: Infusion of Tumor Infiltrating Lymphocytes (10e9-10e10 cells) by iv in 30 Minutes. Followed by daily sc injections of 2 MIE Interleukin-2 for two weeks.
Study: NCT01278459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 4 week treatment, 20mg/day taken orally in tablet form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 4 week treatment, 20mg/day taken orally in tablet form
Study: NCT01008111

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dermabond
Description: On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrogen Peroxide Oxygen producing gel
Description: On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.
Study: NCT03979365

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Envarsus XR
Description: Twice daily tacrolimus vs. Envarsus XR

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus twice daily
Description: Twice daily tacrolimus vs. Envarsus XR
Study: NCT01934153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]Umeclidinium 18.5 mg
Description: Umeclidinium will be supplied as clear, colorless solution, free from visible particulates, single dose, topical solution in clear glass jars. Dosage of 18.5 mg of Umeclidinium per gram is equivalent to 22 mg per gram of the bromide salt.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]Umeclidinium 18.5 mg
Description: Umeclidinium will be supplied as clear, colorless solution, free from visible particulates, single dose, topical solution in clear glass jars. Dosage of 18.5 mg of Umeclidinium per gram is equivalent to 22 mg per gram of the bromide salt.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]Umeclidinium 18.5 mg
Description: Umeclidinium will be supplied as clear, colorless solution, free from visible particulates, single dose, topical solution in clear glass jars. Dosage of 18.5 mg of Umeclidinium per gram is equivalent to 22 mg per gram of the bromide salt.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]Umeclidinium 18.5 mg
Description: Umeclidinium will be supplied as clear, colorless solution, free from visible particulates, single dose, topical solution in clear glass jars. Dosage of 18.5 mg of Umeclidinium per gram is equivalent to 22 mg per gram of the bromide salt.
Study: NCT02692157

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Neurokinin 1,3 antagonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NT-814 50 mg
Description: Neurokinin 1,3 antagonist 50 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NT-814 100 mg
Description: Neurokinin 1,3 antagonist 100 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NT-814 200 mg
Description: Neurokinin 1,3 antagonist 200 mg
Study: NCT02321865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-02
Study: NCT01931267

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tablet Computer Motivated Instruction
Description: Using tablet computer to motivate patient learning breath skill and maintain practive. Research nurse will give 3 times instruction to patients during hospitalization. This arm estimated including 77 subjects

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Systematic Instruction
Description: Research nurse give 3 times systematic instruction during hospitalization This arm estimated including 77 subjects.
Study: NCT04122248

Intervention type: OTHER
Intervention: standard radiographic imaging
Description: standard radiographic imaging

Intervention type: OTHER
Intervention: standard radiographic imaging
Description: standard radiographic imaging
Study: NCT02492451

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endometrial Injury
Description: Endometrial injury in luteal phase of preceding cycle by pipelle canula

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: progesterone (Crinone® %8 vaginal progesterone gel)
Description: Luteal phase support with progesterone (Crinone® %8 vaginal progesterone gel) in IUI cycle Vaginal progesterone gel is administered from second day after insemination until pregnancy testing and is continued in the presence of pregnancy until the 12 weeks of pregnancy.
Study: NCT02649972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib will be administered at a dose of 60mg daily for 21 days on, then 7 days off, in a 28 day treatment cycle. Patients will have the option to discontinue treatment after 12 cycles and will be monitored for disease relapse for an additional 12 months. In the event that disease relapse occurs within the 12 month monitoring period, patients will restart treatment and continue on study. Upon restarting, the assessment schedule will restart at rechallenge cycle 1(RC-1) and all assessments will occur at the frequency and intervals. Cycle 1 Day 15 visits will not be required for patients that restart treatment after relapse. Participants will re-sign consent upon rechallenging.
Study: NCT01395472

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acute Physical Exercise
Description: Patients and healthy volunteers will be submitted to a protocol of progressive maximal exercise until voluntary exhaustion and one weak later to 30 minutes of physical exercise in ventilatory threshold I, both in the same cycloergometer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acute Physical Exercise
Description: Patients and healthy volunteers will be submitted to a protocol of progressive maximal exercise until voluntary exhaustion and one weak later to 30 minutes of physical exercise in ventilatory threshold I, both in the same cycloergometer.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching protocol
Description: TBI patients will be submitted to 30 minutes of stretching exercises composed of 15 exercises that prioritize back, legs and hip.
Study: NCT03341624

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cataract surgery cataract extraction and intraocular implantation
Study: NCT03830294

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: different temperature-controlled breast prostheses
Description: Two types of temperature-controlled breast prostheses were applied to patients in each group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: different temperature-controlled breast prostheses
Description: Two types of temperature-controlled breast prostheses were applied to patients in each group
Study: NCT03394014

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sciatic nerve block
Description: blocking sciatic nerve either at the subgluteal area or the popliteal region for effective anesthesia and analgesia during below knee amputation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sciatic nerve block
Description: blocking sciatic nerve either at the subgluteal area or the popliteal region for effective anesthesia and analgesia during below knee amputation
Study: NCT01437514

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: preoperative short-course radiotherapy
Description: preoperative RT received a total dose of 25 Gy in five fractions during five consecutive days. The clinical target volume included the primary tumor and the mesentery with vascular supply containing the perirectal, presacral, and internal iliac nodes(up to the S1/S2 junction).The recommended upper border was at the level of the promontory. Radiation treatment was delivered with a three-portal technique.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: preoperative short-course radiotherapy
Description: preoperative RT received a total dose of 25 Gy in five fractions during five consecutive days. The clinical target volume included the primary tumor and the mesentery with vascular supply containing the perirectal, presacral, and internal iliac nodes(up to the S1/S2 junction).The recommended upper border was at the level of the promontory. Radiation treatment was delivered with a three-portal technique.
Study: NCT04402827

Intervention type: DIAGNOSTIC_TEST
Intervention: Susceptibility to infection
Description: ACE2 and CD26 receptor study: After genomic DNA extraction and quantification using a NanoDrop-1000, 14 ACE2 SNPs (rs1978124, rs2048683, rs2074192, rs2106809, rs2285666, rs233575, rs4240157, rs4646142, rs4646155, rs4646156, rs4646188, rs4830542, rs6632677, and rs879922) will be studied. In addition, one CD26 (DPP4) SNP (rs7608798) will be analysed (qualitative measure).~SARS-CoV-2 CD4/CD8 T cell response: SARS-CoV-2 peptides (Prot-S, Pros-N and Port-M) will be used to activate CD4 and CD8 T cells. Cytokines released, such as IFNg, TNFa, IL4, IL17A, and IL2, from each cell subset will be measured by flow cytometry (quantitative measure).~KIR characterization: Characterization of the presence of 14 genes plus 2 pseudogenes of KIR gene family (qualitative genotyping) by PCR, mRNA expression profiling (quantitative measures) by RT-PCR, and phenotyping of human NK cells analyzing different KIR receptors (quantitative measure) by flow cytometry, will be analyzed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Susceptibility to infection
Description: ACE2 and CD26 receptor study: After genomic DNA extraction and quantification using a NanoDrop-1000, 14 ACE2 SNPs (rs1978124, rs2048683, rs2074192, rs2106809, rs2285666, rs233575, rs4240157, rs4646142, rs4646155, rs4646156, rs4646188, rs4830542, rs6632677, and rs879922) will be studied. In addition, one CD26 (DPP4) SNP (rs7608798) will be analysed (qualitative measure).~SARS-CoV-2 CD4/CD8 T cell response: SARS-CoV-2 peptides (Prot-S, Pros-N and Port-M) will be used to activate CD4 and CD8 T cells. Cytokines released, such as IFNg, TNFa, IL4, IL17A, and IL2, from each cell subset will be measured by flow cytometry (quantitative measure).~KIR characterization: Characterization of the presence of 14 genes plus 2 pseudogenes of KIR gene family (qualitative genotyping) by PCR, mRNA expression profiling (quantitative measures) by RT-PCR, and phenotyping of human NK cells analyzing different KIR receptors (quantitative measure) by flow cytometry, will be analyzed.
Study: NCT01914432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH16410

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: YH16410 placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YH16410 placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YH16410 placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosuvastatin placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Telmisartan placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan placebo
Study: NCT04640311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daprodustat
Description: Daprodustat will be available as oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daprodustat
Description: Daprodustat will be available as oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daprodustat
Description: Daprodustat will be available as oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daprodustat
Description: Daprodustat will be available as oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daprodustat
Description: Daprodustat will be available as oral tablets.
Study: NCT04206163

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTA-TOC PET/CT
Description: Somatostatin receptor imaging

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTA-TOC PET/CT
Description: Somatostatin receptor imaging

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Analysis of inflammatory biomarkers

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Analysis of inflammatory biomarkers
Study: NCT00856024

Intervention type: BIOLOGICAL
Intervention: Peginterferon alfa-2b
Description: PegIntron 80 μg, PegIntron 100 μg, or PegIntron 120 μg. The duration of the complete treatment and the doses of pegylated interferon alfa 2b should have been prescribed according to local guidelines, and according to the investigating physician's orientation.
Study: NCT03255226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Tolvaptan 1% granules or tolvaptan 15 mg tablet with water once daily.
Study: NCT03107442

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: 12-weeks aerobic exercise intervention based on the physical activity guidelines from the American College of Sports Medicine (≥150 min/week of moderate to vigorous \[40-85% of the individual's heart rate reserve\] exercise). Participants will perform the exercise on treadmills at the hospital. The volume and intensity of the exercise will progressively increase throughout the 12 weeks.
Study: NCT04645927

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: flaxseed beverage
Description: Pizzey Ingredients Inc. introduced a flax beverage product that is a plant-based beverage product that is designed as an alternative to non-diary milks (almond milk \& soy milk). Each 330 ml serving of flax beverage contains 15 g flaxseed, which amounts to 3.75 gm of omega-3 fatty acid. Preventing MCI or even AD may be within reach, if appropriate measures are taken early enough using strategies such as dietary supplementation.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: control beverage
Description: Oat fibre control. For 180 days (6 months) participants will consume 2 servings of 330 ml of placebo beverage (i.e. normal fiber beverage; control) per day.
Study: NCT04666012

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCLD-CoV19
Description: Replication-defective human adenovirus type 5/35 vector based vaccine expressing S protein of SARS-CoV-2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCLD-CoV19
Description: Replication-defective human adenovirus type 5/35 vector based vaccine expressing S protein of SARS-CoV-2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCLD-CoV19
Description: Replication-defective human adenovirus type 5/35 vector based vaccine expressing S protein of SARS-CoV-2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCLD-CoV19
Description: Replication-defective human adenovirus type 5/35 vector based vaccine expressing S protein of SARS-CoV-2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCLD-CoV19
Description: Replication-defective human adenovirus type 5/35 vector based vaccine expressing S protein of SARS-CoV-2.
Study: NCT03890159

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Assited Cognitive rehabilitation
Description: Patients will receive their therapies 1 day a day, 2-3 days a week. The computer-aided cognitive rehabilitation group will perform simulation-based exercises, including exercises related to attention, in a special computer program (Cogniplus TR version) during therapy hours. The total duration of intervention will be 1 month.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional Cognitive Rehabilitation
Description: Patients will receive their therapies 1 day a day, 2-3 days a week. The home (paper pen) exercise group will take the necessary exercises on paper suitable for their respective levels and the daily tasks suitable for their functional needs and interests. The total duration of intervention will be 1 month.
Study: NCT02536625

Intervention type: OTHER
Intervention: prospective study
Study: NCT02560207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefotaxime
Description: To assess the influence of administration route on target attainment cefotaxime is administered via two IV routes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefotaxime
Description: To assess the influence of administration route on target attainment cefotaxime is administered via two IV routes.